These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1027 related items for PubMed ID: 22998182

  • 1. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S, Zhu X, Schroder FH, Roobol MJ.
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [Abstract] [Full Text] [Related]

  • 2. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [Abstract] [Full Text] [Related]

  • 3. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [Abstract] [Full Text] [Related]

  • 4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [Abstract] [Full Text] [Related]

  • 6. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
    Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ.
    BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
    [Abstract] [Full Text] [Related]

  • 7. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level.
    McGuire BB, Helfand BT, Loeb S, Hu Q, O'Brien D, Cooper P, Yang X, Catalona WJ.
    BJU Int; 2012 Jun; 109(12):1764-9. PubMed ID: 22017732
    [Abstract] [Full Text] [Related]

  • 8. Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
    Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC, Catalona WJ.
    J Urol; 2005 Jul; 174(1):126-30. PubMed ID: 15947596
    [Abstract] [Full Text] [Related]

  • 9. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
    Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M.
    BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
    [Abstract] [Full Text] [Related]

  • 10. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Apr; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 12. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
    Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, D'Amico AV.
    Cancer; 2008 Dec 01; 113(11):3146-52. PubMed ID: 18932254
    [Abstract] [Full Text] [Related]

  • 13. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
    van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, van Leeuwen PJ, Roobol MJ, Schröder FH, Hugosson J, Swedish and Dutch sections of the European Randomized Study of Screening for Prostate Cancer.
    Cancer; 2010 Mar 01; 116(5):1281-90. PubMed ID: 20066716
    [Abstract] [Full Text] [Related]

  • 14. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.
    BJU Int; 2012 Dec 01; 110(11):1654-60. PubMed ID: 23043563
    [Abstract] [Full Text] [Related]

  • 15. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors.
    Joniau S, Hsu CY, Gontero P, Spahn M, Van Poppel H.
    Scand J Urol Nephrol; 2012 Jun 01; 46(3):164-71. PubMed ID: 22364377
    [Abstract] [Full Text] [Related]

  • 16. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.
    Fairey AS, Daneshmand S, Skinner EC, Schuckman A, Cai J, Lieskovsky G.
    Urol Oncol; 2014 Feb 01; 32(2):85-91. PubMed ID: 24183191
    [Abstract] [Full Text] [Related]

  • 17. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.
    BJU Int; 2012 Jul 01; 110(1):36-42. PubMed ID: 22085203
    [Abstract] [Full Text] [Related]

  • 18. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG.
    BJU Int; 2012 Jun 01; 109(12):1794-800. PubMed ID: 21992536
    [Abstract] [Full Text] [Related]

  • 19. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.
    BJU Int; 2012 Oct 01; 110(8):1116-21. PubMed ID: 22540922
    [Abstract] [Full Text] [Related]

  • 20. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD, Goldberg JD, Hochman T, Lepor H.
    Eur Urol; 2011 Sep 01; 60(3):548-53. PubMed ID: 21652145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.